Chicago Equity Partners Upped Its Celgene (CELG) Stake; Alimera Sciences Has 1.07 Sentiment

November 15, 2017 - By reb123z

Alimera Sciences, Inc. is a pharmaceutical company. The company has market cap of $84.36 million. The Firm is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It currently has negative earnings. The Firm operates through two divisions: U.S. and International.

Chicago Equity Partners Llc increased Celgene Corp (CELG) stake by 6.08% reported in 2017Q2 SEC filing. Chicago Equity Partners Llc acquired 5,260 shares as Celgene Corp (CELG)’s stock declined 3.49%. The Chicago Equity Partners Llc holds 91,740 shares with $11.91 million value, up from 86,480 last quarter. Celgene Corp now has $77.83B valuation. The stock declined 0.55% or $0.54 reaching $98.32 on the news. About 31,392 shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since November 15, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Among 31 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 2 Sell and 9 Hold. Therefore 65% are positive. Celgene Corporation had 110 analyst reports since July 21, 2015 according to SRatingsIntel. Leerink Swann initiated the shares of CELG in report on Friday, February 5 with “Market Perform” rating. The firm earned “Underweight” rating on Monday, October 23 by Morgan Stanley. The firm has “Buy” rating by Oppenheimer given on Wednesday, June 14. The firm has “Buy” rating given on Thursday, September 7 by Stifel Nicolaus. On Friday, October 27 the stock rating was maintained by UBS with “Buy”. Oppenheimer maintained Celgene Corporation (NASDAQ:CELG) rating on Thursday, July 27. Oppenheimer has “Buy” rating and $17500 target. The firm has “Buy” rating by Mizuho given on Wednesday, July 26. Cowen & Co maintained Celgene Corporation (NASDAQ:CELG) on Thursday, July 27 with “Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by Credit Suisse on Tuesday, April 19. The company was maintained on Tuesday, October 17 by BMO Capital Markets.

Since June 15, 2017, it had 0 insider buys, and 3 insider sales for $2.36 million activity. CASEY MICHAEL D also sold $1.16 million worth of Celgene Corporation (NASDAQ:CELG) shares. VESSEY RUPERT also sold $575,038 worth of Celgene Corporation (NASDAQ:CELG) on Thursday, June 15. 5,000 shares were sold by Friedman Michael A, worth $625,000.

Investors sentiment increased to 1.34 in Q2 2017. Its up 0.21, from 1.13 in 2017Q1. It increased, as 60 investors sold CELG shares while 390 reduced holdings. 110 funds opened positions while 494 raised stakes. 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported. 65,505 are owned by Sit Inv Associate. Mitsubishi Ufj Secs Limited stated it has 0.61% of its portfolio in Celgene Corporation (NASDAQ:CELG). Quantitative Management Lc reported 486,800 shares. Uss Investment Management Ltd reported 1.12% stake. Gm Advisory Gp stated it has 3,208 shares. Bancorpsouth reported 0.04% of its portfolio in Celgene Corporation (NASDAQ:CELG). 10,504 are owned by Aspiriant Lc. 13,542 were reported by Insight Capital Mgmt Inc. Scholtz And Communication Ltd Llc stated it has 9,975 shares. Vantage Invest Advisors Llc accumulated 0% or 100 shares. Ww Invsts stated it has 635,000 shares or 0.02% of all its holdings. Financial Architects accumulated 1,881 shares or 0.04% of the stock. Md Sass Invsts Inc invested 5.47% in Celgene Corporation (NASDAQ:CELG). Asset Mngmt One holds 1.24M shares. Barnett Inc has invested 0.05% in Celgene Corporation (NASDAQ:CELG).

Chicago Equity Partners Llc decreased Copa Holdings Sa (NYSE:CPA) stake by 52,615 shares to 173,155 valued at $20.26 million in 2017Q2. It also reduced Hunt J B Trans Svcs Inc (NASDAQ:JBHT) stake by 3,825 shares and now owns 8,070 shares. Regions Finl Corp New (NYSE:RF) was reduced too.

Analysts await Alimera Sciences Inc (NASDAQ:ALIM) to report earnings on March, 7. They expect $-0.03 EPS, up 70.00% or $0.07 from last year’s $-0.1 per share. After $-0.04 actual EPS reported by Alimera Sciences Inc for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.